Cardiac gene editing holds promising potential in revolutionizing the landscape of cardiovascular medicine. This innovative field involves precisely modifying the genetic code within cardiac cells to address and rectify underlying genetic factors contributing to heart diseases. By leveraging advanced molecular tools such as CRISPR-Cas9, researchers aim to target specific genes associated with cardiac conditions, paving the way for personalized therapeutic interventions. The ability to edit genes directly in cardiac tissue opens new avenues for treating congenital heart disorders, genetic predispositions, and other cardiovascular ailments. While still in the early stages of development, cardiac gene editing represents a cutting-edge approach that holds great promise for advancing our understanding of cardiac health and fostering breakthroughs in tailored treatments for individuals with various cardiovascular conditions.
Title : Novel mechanisms and new therapeutics for right heart failure in pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Movement is medicine
Steve Cohen, Medvesta Hypnosis Healthcare, United States
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Fats of life, the skinny on novel lipid therapies beyond statins
Ahdy Wadie Helmy, Indiana University School of Medicine, United States
Title : Novel ways of cardiovascular risk assessment
Syed Raza, Awali Hospital, Bahrain
Title : Cardiovascular nanomedicine: Stopping strokes, unclogging arteries and restoring heart function
Thomas J Webster, Hebei University of Technology, China